MedTrace Logo

Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma

NCT02107950 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2018-08-15

No results posted yet for this study

Summary

The purpose of this study is to determine whether DCVAC/OvCa added to chemotherapy (carboplatin and gemcitabine as second line chemotherapy) may result in prolongation of progression free survival (PFS).

Conditions

  • Ovarian Neoplasms
  • Ovarian Cancer (OvCa)
  • Ovarian Epithelial Cancer

Interventions

BIOLOGICAL

DCVAC/OvCa in parallel with chemotherapy

DCVAC/OvCa is the experimental therapy added on to Carboplatin and Gemcitabine

DRUG

Standard of Care

Carboplatin and Gemcitabine is Standard of Care First Line Chemotherapy

Sponsors & Collaborators

  • SOTIO a.s.

    lead INDUSTRY

Principal Investigators

  • Ales Horacek · Accord Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2016-11-30
Completion
2017-05-17

Countries

  • Czechia
  • Germany
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02107950 on ClinicalTrials.gov